Industry Reports
MIMETAS Secures 20 Million Dollar Series B Financing
MIMETAS, leader in organ-on-a-chip products and tissue models, has secured 20.5 million USD in financing from an international syndicate from Asia and Europe. MIMETAS will use the proceeds of this Series B financing round to expand...
Industry Reports
Tracelink Global Drug Supply Report 2017
 TraceLink’s Global Drug Supply, Safety and Traceability Report survey highlights a lack of industry readiness for U.S. DSCSA, and concerns in European nations on readiness for the February 2019 EU FMD compliance deadline Organization Breakdown* 2%...
Industry Reports
Takeda Statement Regarding Shire plc
Takeda Pharmaceutical Company Limited notes the share price movement with respect to Shire plc. Takeda confirms that it is considering making an approach to Shire regarding a possible offer for the company. Takeda’s consideration of such...
Industry Reports
LANXESS posts record earnings for 2017 and a good start to the new fiscal year
Sales up 25.5 percent to EUR 9.66 billion in fiscal year 2017 Strong volume increase in all segments EBITDA pre exceptionals up by 29.6 percent to EUR 1.29 billion EBITDA margin pre exceptionals...
Industry Reports
TxCell 2017 financial results and 2018 objectives
TxCell SA , a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, announces its financial results for 2017 and its objectives for 2018. “In 2017, TxCell successfully finalized its...
Industry Reports
Ardena acquires ChemConnection adding API expertise
Contract development and manufacturing organisation (CDMO) Ardena has acquired ChemConnection, a leading contract manufacturer of novel active pharmaceutical ingredients (APIs) and nanomedicines.
Originating from Organon and Merck Sharp & Dohme (MSD) in 2012, Netherlands-based ChemConnection has rapidly evolved to become...
Industry Reports
Sessa Capital Im LP decline Its Bristol Myers Squibb Co (BMY) Position by $272.76 Million
Investors sentiment increased to 1.03 in Q3 2017. Its up 0.08, from 0.95 in 2017Q2. It is positive, as 62 investors sold BMY shares while 519 reduced holdings. 137 funds opened positions while 460 raised stakes. 1.11 billion shares...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read